

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1079CONS	SERIAL NO.: Not yet known 10/057,630			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Ronald M. BURCH, et al.				
									FILING DATE: Herewith		GROUP: Not Yet Known 1639		
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
MM	AA	5	8	5	9	2	5	7	01/12/99	Talley	548	247	08/14/98
	AB	5	8	6	3	9	2	2	01/26/99	Mayer, et al.	514	270	07/02/99
	AC	5	8	4	0	7	3	1	11/24/98	Mayer, et al.	514	289	08/02/95
	AD	5	8	6	9	4	9	8	02/09/99	Mayer, et al.	514	282	07/07/97
	AE	5	8	6	1	4	1	9	01/19/99	Dube, et al.	514	334	07/11/97
	AF	5	7	8	9	4	1	3	08/04/98	Black, et al.	514	255	01/21/97
	AG	5	6	0	4	2	6	0	02/18/97	Guay, et al.	514	605	11/04/93
	AH	5	4	5	8	8	7	9	10/17/95	Singh, et al.	424	400	09/30/94
	AI	5	5	1	6	8	0	3	05/14/96	Raffa	514	570	03/01/95
	AJ	5	8	4	3	4	6	8	12/01/98	Burkoth, et al.	424	448	05/13/96
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
MM	AK	Differential Inhibition of Cyclooxygenase-1 (COX-1) and -2 (COX) By NSAIDS: Consequences on Anti-Inflammatory Activity Versus Gastric and Renal Safety, M. Pairet, et al., Inflammopharmacology 4: 61-70, (1996).											
	AL	Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation, Derek W. Gilroy, et al. European J. Pharm 355 pp 211-217, (1998).											
	AM	Cyclooxygenases 1 and 2, J.R. Vane, et al. Annu. Rev. Pharmacol. Toxicol. 38: 97-121, (1998).											
	AN	Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor, Tatsuo Yamamoto, et al. Brain Research 739:104-110, (1996)											
	AO	Comparative Analgesic Efficacy of Nimesulide and Diclofenac Gels after Topical Application on the Skin, S. Sengupta, et al., Skin Pharmacol. And Applied Skin Phys. 11:273-278, (1998).											
	AP	Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord, Cartiona Hay and Jacqueline de Belleroche, Neuro Report 8, 1249-1251, (1997).											
	AQ	The Mechanisms of Action of NSAIDs in Analgesia, Jeremy N. Cashman, Drugs 52 Supp. 5:13-23, (1996).											
	AR	Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation, D.W. Gilroy, et al. Inflamm. Res. 47:79-85, (1998).											
MM	AS	Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date, Don E. Griswold and Jerry L. Adams, Medicinal Research Reviews, Vol. 16, No. 2, pp. 181-206, (1996).											
EXAMINER							DATE CONSIDERED				8/20/04		
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>													

FORM PTO-1449 (REV. 7-80)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO.: 200.1079CONS	SERIAL NO.: Not Yet Known 10/057,630		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Ronald M. BURCH, et al.			
						FILING DATE: Not Yet Known	GROUP: Not Yet Known 1639		
U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>MM</i>	BA								
	BB								
	BC								
	BD								
	BE								
	BF								
	BG								
	BH								
	BI								
	BJ								
	BK								
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
									YES NO
	BL								
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
<i>MM</i>	BM	Cyclooxygenase in biology and disease, Raymond N. Dubois, et al., FASEB J. Vol. 12 pp. 1063-1073 (1998).							
	BN	Pharmacology of Meloxicam, A new Non-Steroidal Anti-Inflammatory Drug With An Improved Safety Profile Through Preferential Inhibition of COX-2, G. Engelhardt, British J. Rheumatology, 35 (supp 1):4-12, (1996)							
	BO	Cyclooxygenase 1 Contributes to Inflammatory Responses in Rats and Mice: Implications for Gastrointestinal Toxicity, John L. Wallace, et al. Gastroenterology, 115:101-109 (1998).							
	BP	Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications, M. Pairet and G. Engelhardt, Fundam. Clin. Pharmacol. 10:1-15, (1996).							
	BO	Involvement of Prostaglandins Produced by Cyclooxygenase-1 in Murine Visceralnociception Induced by Phenylquinone, Hidenobu Kusuhara, et al. Prostaglandins 55: 43-49, (1998).							
<i>MM</i>	BR	Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats. D. Dirig, et al. J. Pharmacol. And Experimental Therapeutics Vol. 285, No. 3, pp 1031-1038.							
EXAMINER	<i>MM</i>				DATE CONSIDERED				<i>8/26/04</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CONS		SERIAL NO.: Not Yet Known 10/057,630						
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.								
				FILING DATE: Not Yet Known 1639		GROUP: Not Yet Known						
U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	CA											
	CB											
	CC											
	CD											
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
	CE	9	9	0	7	4	1	3	2/18/99	WO		
	CF	9	9	3	2	1	1	9	7/1/99	WO		
	CG											
	CH											
	CI											
	CJ											
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
	CK	Effect of meloxicam on postoperative pain after abdominal hysterectomy, J.P. Thompson et al. British Journal of Anaesthesia 84 (2) 151-4 (2000).										
	CL	Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats. C.S. Wong et al., British Journal of Anaesthesia 85 (5) 747-51 (2000).										
	CM	Cyclooxygenase inhibitors increase morphine effects on mesolimbic dopamine neurons, M. Melis, et al. Eur. J. Pharmacology 387 (1) R1-R3 (2000).										
	CN	Synergistic antialloodynic effects of spinal morphine with ketorolac and selective COX-1 and COX-2 inhibitors in nerve-injured rats, J.M. Lashbrook, et al. Pain 82 (1) 65-72 (1999).										
	CO	Enhancement of opioid inhibition of gaba-ergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones, Vaughn et al. British Journal of Pharmacology 123 (8) 1479-81 (1998).										
EXAMINER					DATE CONSIDERED							
					8/26/04							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO.: 200.1079CONS	SERIAL NO.: Not Yet Known 10/057, 630			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)										APPLICANT(S): Ronald M. BURCH, et al.				
										FILING DATE: Not Yet Known 1639				
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>MM</i>	DA	5	4	7	4	9	9	5	12/12/95	Ducharme et al.	514	241	01/10/94	
	DB	5	6	9	1	3	7	4	11/25/97	Black et al.	514	473	05/18/95	
	DC													
	DD													
	DE													
	DF													
	DG													
	DH													
	DI													
	DJ													
	DK													
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
													YES	NO
	DL													
	DM													
	DN													
	DO													
	DP													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	DQ													
	DR													
	DS													
EXAMINER	<i>MM</i>											DATE CONSIDERED	<i>8/20/04</i>	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1079CON5	SERIAL NO.: Not Yet Known <i>10/057, 630</i>				
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Ronald M. BURCH, et al.					
									FILING DATE: Not Yet Known <i>1639</i>	GROUP: Not Yet Known <i>1639</i>				
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
<i>MM</i>	EA	3	8	0	0	0	4	1	03/26/74	Miller, et al.	424	273	03/02/71	
	EB	4	3	2	2	4	2	7	03/30/82	Buyinski, et al.	424	260	04/16/81	
	EC	4	3	3	8	3	2	4	06/06/82	Gardocki	424	268	03/17/81	
	ED	4	4	0	4	2	1	0	09/13/83	Schmidt	424	260	06/30/82	
	EE	4	4	0	7	8	0	4	10/04/83	Schmidt	424	260	06/30/82	
	EF	4	4	0	7	8	0	5	10/04/83	Schmidt	424	260	06/30/82	
	EG	4	4	6	4	3	7	6	08/07/84	Sunshine, et al.	424	253	10/11/83	
	EH	4	4	8	6	4	3	6	12/04/84	Sunshine, et al.	424	253	03/11/83	
<i>MM</i>	EI	4	4	8	9	0	8	0	12/18/84	Lomen	424	260	12/06/82	
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO
<i>MM</i>	EJ	2	0	2	3	3	4	9	02/18/91	Canada	A61K	31/44		
	EK	0	2	7	4	8	4	5	07/20/88	EP (A1)	A61K	31/19		
<i>MM</i>	EL	0	3	8	8	1	2	5	09/19/90	EP (A1)	A61K	31/485		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
<i>MM</i>	EM	Pharmacokinetics and Drug Input Characteristics for a Diclofenac-Codeine Phosphate Combination Following Oral and Rectal Administration A. Hansen, et al. Arzneim-Forsch./Drug Res. 46 (II) 57-63 (1996).												
<i>MM</i>	EN	Comparison of a Standard Ibuprofen Treatment Regimen with a New Ibuprofen/Paracetamol/Codeine Combination in Chronic Osteo-arthritis G.K. Vlok, et al. Univ. Stellenbosch and Tygerberg Hospital, Dept. Orthopaedic Surg. pp 3-6, (1987).												
	EO													
	EP													
	EQ													
	ER													
EXAMINER <i>MM</i>		DATE CONSIDERED									<i>8/24/04</i>			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1079CONS	SERIAL NO.: Not Yet Known <u>10/057,630</u>			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Ronald M. BURCH, et al.				
									FILING DATE: Not Yet Known <u>163.9</u>				
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<u>MM</u>	FA	4	5	6	7	1	8	3	01/28/86	Sunshine, et al.	514	264	12/12/83
	FB	4	5	6	9	9	3	7	02/11/86	Baker, et al.	514	282	02/11/83
	FC	4	5	7	1	4	0	0	02/18/86	Arnold	514	282	12/18/84
	FD	4	5	8	7	2	5	2	05/06/86	Arnold	514	282	12/18/84
	FE	4	6	1	9	9	3	4	12/28/86	Sunshine, et al.	514	277	07/08/85
	FF	4	6	9	0	9	2	7	09/01/87	Voss, et al.	514	282	02/03/86
	FG	4	8	3	9	1	7	6	06/13/89	Pahkhania, et al.	424	465	12/08/87
	FH	4	8	4	4	9	0	7	07/04/89	Elger, et al.	424	465	08/14/86
	FI	4	9	2	7	8	5	4	05/22/90	Sunshine, et al.	514	570	08/21/89
	FJ	5	1	6	4	3	9	8	12/17/92	Sims, et al.	514	282	04/01/91
	FK	5	1	9	0	9	4	7	03/02/93	Riess, et al.	514	282	08/16/91
<u>MM</u>	FL	5	2	4	0	6	9	4	08/31/93	Gwaltney, Jr.	424	45	12/19/91
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
<u>MM</u>	FM	0	0	6	8	8	3	8	06/25/82	EP (A1)	A61K	31/485	
<u>MM</u>	FN	0	0	6	8	8	3	8	06/25/82	EP (B1)	A61K	31/485	
<u>MM</u>	FO	2	0	8	1	6	0	4	05/01/95	Canada	A61K	031/135	
	FP												
	FO												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	FR												
	FS												
	FT												
EXAMINER								DATE CONSIDERED		8/24/04			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1079CON5	SERIAL NO.: Not Yet Known <u>10/057, 630</u>				
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Ronald M. BURCH, et al.					
									FILING DATE: Not Yet Known <u>1639</u>	GROUP: Not Yet Known				
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>ML</i>	GA	5	4	0	9	9	4	4	04/25/95	Black, et al.	514	359	03/12/93	
	GB	5	4	3	6	2	6	5	06/25/95	Black, et al.	514	420	11/12/93	
	GC	5	5	1	0	3	6	8	04/23/96	Lau, et al.	514	419	05/22/95	
	GD	5	5	2	1	2	1	3	05/28/96	Prasit, et al.	514	443	08/29/94	
	GE	5	5	5	0	1	4	2	08/27/96	Ducharme et al.	514	365	05/08/95	
	GF	5	5	5	2	4	2	2	09/03/96	Gauthier, et al.	514	368	01/11/95	
	GG	5	6	0	4	2	5	3	02/18/97	Lau, et al.	514	415	05/22/95	
<i>MM</i>	GH	5	6	3	9	7	8	0	06/17/97	Lau, et al.	514	419	05/22/95	
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	GI													
	GJ													
	GK													
	GL													
	GM													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	GN	Anti-inflammatory Drugs and Their Mechanism of Action J.R. Vane, et al. Inflamm. Res. 47, Supplement 2 (1998).												
	GO													
	GP													
	GQ													
	GR													
EXAMINER	<i>ML</i>								DATE CONSIDERED			<i>8/12/04</i>		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1079CONSSERIAL NO.: Not Yet Known
10/057, 630

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: Not Yet Known

GROUP: Not Yet Known

1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HD							
HE							
HF							
HG							
HH							
HI							
HJ							
HK							

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
HL								
HM								
HN								
HO								
HP								

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)


<i>M</i>	HQ	Rorarius et al., "Non-Steroidal Anti-Inflammatory Drugs for PostOperative Pain Relief," Curr. Opin. In Anaesthesiology, 7, 358-362. (1994)
<i>M</i>	HR	Hanses et al. "Pharmacokinetics and Drug input Characteristics for a Diclofenac-Codeine Phosphate Combination Following Oral and Rectal Administration," Arzneim.-Forsch./Drug Res., 46(II), Nr. 1,57-63. (1996)
	HS	Merck Index, Twelfth Edition, Merck & Co. Publishers, page 1194. (1996)
<i>M</i>	HT	Goodman and Gillman's: Pharmaceutical Basis of Therapeutics. "Chapter 22: Opioid Analgesics and Antagonists", MacMillan Publishing Co., Inc., pp-494-497, esp. Table 22-1, p. 496. (1980)

EXAMINER

DATE CONSIDERED

8/26/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1079US		SERIAL NO.: 09/154,354 10/057,630			
 LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Ronald M. BURCH, et al.					
									FILING DATE: September 17, 1998		GROUP: 1627 1639			
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION	
		AA	0	6	5	4	2	6					3	YES
<i>MM</i>	AA	0	6	5	4	2	6	3	05/24/95	EP (A1)	A61K	31/135		
<i>MM</i>	AB	0	6	5	4	2	6	3	05/24/95	EP (B1)	A61K	31/135		
<i>MM</i>	AC	9	7	1	7	9	7	8	05/22/97	WO	A61K	33/00		
<i>MM</i>	AD	9	7	2	5	9	8	8	07/24/97	WO	A61K	31/495		
<i>MM</i>	AE	9	7	3	2	8	5	7	09/12/97	WO	C07D	241/104		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
<i>MM</i>	AF	Dray et al. New Pharmacological Strategies for Pain Relief. <u>Annual Review of Pharmacology & Toxicology</u> , 36, pp. 253-280. (1996).												
	AG	Brasseur, L. <u>Revue des therapeutiques pharmacologiques actuelles de la douleur</u> . Drugs, 53 Suppl 2, pp. 10-17. (1997)												
	AH	Rang et al. New molecules in analgesia. <u>British Journal of Anesthesia</u> , 75, pp. 145-156 (1995)												
	AI	Beaver, WT. Combination Analgesics. <u>American Journal of Medicine</u> , 77 (Suppl 3A), pp. 38-53. (1984).												
	AJ	Beaver, WT. Chapter 29: Nonsteroidal Antiinflammatory Analgesics and Their Combinations with Opioids. In <u>Evaluation and Treatment of Chronic Pain</u> , 2 nd ed., William & Wilkins pp. 363-383. (1992).												
	AK	Goodman & Gilman's. <u>The Pharmacological Basis of Therapeutics</u> , 9 th Edition. McGraw-Hill, New York, pp 535 and 551-552.												
	AL	Picard et al. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. <u>Pain</u> , 73, 3 pp. 401-406. (1997).												
	AM	Etches et al. Continuous Intravenous Administration of Ketorolac Reduces Pain and Morphine Consumption After Total Hip or Knee Arthroplasty. <u>Anesthesia & Analgesia</u> , 81 (6), pp. 1175-1180. (1995).												
	AN	Hodsman et al. The morphine sparing effects of diclofenac sodium following abdominal surgery. <u>Anaesthesia</u> , 42(9), pp. 1005-1008. (1987).												
	AO	Kaasalainen et al. Developments in the treatment of cancer pain in Finland: The third nation-wide survey. <u>Pain</u> , 70, 2-3, pp. 175-183. (1997).												
	AP	Sunshine et al. Analgesic Efficacy of a Hydrocodone with Ibuprofen Combination Compared with Ibuprofen Alone for the Treatment of Acute Postoperative Pain. <u>Journal of Clinical Pharmacology</u> , 37 (10), pp. 908-915. (1997).												
	AQ	Insel. Chapter 27: Analgesic-Anipyretic and Anti-Inflammatory Agents. In Hardman, ed., <u>Goodman & Gilman's The Pharmacological Basis of Therapeutics</u> , 9 th Edition. McGraw-Hill, New York, pp. 654-655. (1996).												
	AR	Polisson. Non-steroidal Anti-Inflammatory Drugs: Practical and Theoretical Consideration in Their Selection. <u>The American Journal of Medicine</u> , 100 (Suppl 2A), pp. 2A-31S - 2A-36S. (1996).												
	AS	Vane, J. Towards a better aspirin. <u>Nature</u> , 367, pp. 215-216. (1994).												
<i>MM</i>	AT	Simon, L.S. Nonsteroidal Antiinflammatory Drugs and Their Effects: The Importance of COX 'Selectivity'. <u>Journal of Clinical Rheumatology</u> , 2 (3), pp. 135-140. (1996).												
EXAMINER	<i>MM MM</i>							DATE CONSIDERED <i>8/26/98</i>						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

RECEIVED
DEC 11 4 2002
TECH CENTER 1600/2900

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: 09/154,354 10/057,630
OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Ronald M. BURCH, et al.		
		FILING DATE: September 17, 1998	GROUP: 1027 1639	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)				
	BA	Van Ryn et al. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects, and therapeutic potential. <u>Expert Opinion On Investigational Drugs</u> . pp. 609-614. (1997).		
	BB	Vane et al. New insights into the mode of action of anti-inflammatory drugs. <u>Inflammation Research</u> . 44, (No.1), pp 1-10 (1995).		
	BC	Engelhardt. Meloxicam: A Preferential Inhibitor of COX-2. <u>British Journal of Rheumatology</u> . 34, Abstract Suppl. 1, p. 48. (1995). Abstract.		
	BD	Lane, N.E. Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors. <u>Journal of Rheumatology</u> . Vol. 24, Suppl 49, pp. 20-24. (1997).		
	BE	Boyce et al. L-745,337: A Selective Inhibitor of Cyclooxygenase-2 Elicits Antinociception But Not Gastric Ulceration in Rats. <u>Neuropharmacology</u> Vol. 33, pp. 1609-1611. (1994).		
	BF	Donelly et al. COX-II Inhibitors - a new generation of safer NSAIDS? <u>Alimentary Pharmacology and Therapeutics</u> , 11, 2, pp. 227-236. (1997).		
	BG	Wallace, J.L. Nonsteroidal Anti-inflammatory Drugs and Gastroenteropathy: The Second Hundred Years. <u>Gastroenterology</u> , 112, 3, pp. 1000-1016. (1997).		
	BH	Robinson, D.R. Regulation of Prostaglandin Synthesis by Antiinflammatory Drugs. <u>J Rheumatology</u> , 24, Suppl. 47, pp. 32-39. (1997).		
	BI	Tannenbaum et al. An Evidence-Based Approach to Prescribing NSAIDS in Musculoskeletal Disease: A Canadian Consensus. <u>Canadian Medical Association Journal</u> , 155, 1, pp. 77-88. (1996).		
	BJ	Mehlisch et al. Analgesic Efficacy and Plasma Levels of a Highly Selective Inhibitor of COX-2 (SC-58635, SC) in Patients with Postsurgical Dental Pain. <u>Journal of Clinical Pharmacology</u> , 37, 9, 863. (1997). Abstract.		
	BK	Dammann. Selective COX-2 Inhibition: Its Relevance for NSAID-Gastrointestinal Toxicity. <u>Gut</u> , 39, Suppl. 3, A151. (1996). Abstract.		
	BL	Penning et al. Synthesis and Biological Evaluation of the 1, 5 -diarylpyrazole class of cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). <u>Journal Of Medicinal Chemistry</u> , 40(9), 1347-65. (1997).		
	BM	Lipsky et al. Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis. <u>Journal Of Rheumatology</u> , 24 Suppl 49, pp. 9-14. (1997).		
	BN			
	BO			
	BP			
	BQ			
	BR			
	BS			
	BT			
EXAMINER		DATE CONSIDERED 12/05/98		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
DEC 04 1998
TECH CENTER 1600
1600 MSC

FORM PTO-1449 (REV. 7-30-94)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: 091154,354	10/057,630	
LIST OF PRIOR ART CITED BY APPLICANT <i>DEC. 02 2002 (Use several sheets if necessary)</i>		APPLICANT(S): Ronald M. BURCH, et al.					
		FILING DATE: September 17, 1998	GROUP: 1627 1630				
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
AM	AH	0 7 3 4 2 7 5	11/04/1997	Australia	C07D	261/08	YES
AN							NO
AO							
AP							
AQ							
AR							
AS							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)				RECEIVED TECH CENTER 1600 DEC 04 2002			
AM							
AN							
AO							
AP							
AQ							
AR							
AS							
EXAMINER	<i>Ronald M. BURCH</i>			DATE CONSIDERED	<i>8/26/04</i>		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.